Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;12(8):117. doi: 10.1038/s41408-022-00712-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — A Model of the relative percentage of myeloid marker expression over the course of normal HSPC differentiation. The SLA is defined by the combination of expressions of five myeloid markers plus HLA-DR to differentiate GP-L (HLA-DR+) and MP-L (HLA-DR−); +≥20% of blasts; −<20% of blasts; +/− marker can be positive or negative. B Principal component analyses of 945 AML using the percentage of AML blasts expression of 16 markers by flow cytometry (CD4, CD7, CD13, CD33, CD117, MPOc, CD34, HLA-DR, CD56, CD64, CD38, CD65, CD16, CD14, CD11b, CD123). AML patients were classified according to their SLA as detailed in (A). C Pie chart of 2087 AML from TUH cohort segregated according to their SLA. D FAB classification according to SLA in the TUH cohort. Fisher’s exact test compared FAB classification in one SLA to all others. E Extramedullary involvement in SLA (see Table 1 for details). F Boxplots of leukocytosis at diagnosis in TUH cohort. G CFU-L in TUH cohort. Statistical analysis was performed comparing one SLA to all others (Mann–Whitney test).